UK High Court Upholds Novartis’s Sacubitril Valsartan SPC: What Is The Relevant “product”?
The UK High Court ruled in favor of Novartis, upholding its SPC for the combination of sacubitril and valsartan in Entresto®. The court defined the protected 'product' as the combination of these active ingredients, not the specific co-crystal formulation. This decision impacts Novartis's patent protection and potential competition from generic versions.
How this was made
The 30-second read
Why it matters
Novartis retains exclusive rights to Entresto, preserving its revenue stream from heart‑failure therapy.
Market read
The ruling secures Novartis's patent protection, offering modest upside potential for its stock while setting a legal precedent for other pharma SPC cases.
What to watch
Potential future regulatory changes to SPC definitions could alter the protection scope.
Background
The decision clarifies how UK courts define the "product" for supplementary protection certificates, focusing on active ingredient combinations rather than specific formulations.
Ticker impact
UK High Court upheld Novartis's SPC for Entresto, confirming protection of the sacubitril‑valsartan combination.
potential modest upside as the SPC protection reduces competitive pressure.
Legal affirmation of the SPC removes uncertainty for the product, which may be reflected in a slight share price lift.
Market effects
Reinforces SPC interpretation for combination drugs, affecting other pharma companies with similar patents.
UK legal precedent may influence European SPC strategies.
Limited to companies with combination‑drug SPCs; broader market impact minimal.
Counterpoint
If competitors can challenge the SPC on other grounds, the protection may be less durable.
Key entities
- CompanyNovartis AG
Swiss pharmaceutical firm with US‑listed ticker NVS.
- CompanyAccord Healthcare Ltd
UK generic drug maker that challenged the SPC.
